US9849244B2 - Dose setting mechanism for priming a drug delivery device - Google Patents

Dose setting mechanism for priming a drug delivery device Download PDF

Info

Publication number
US9849244B2
US9849244B2 US13/320,639 US201013320639A US9849244B2 US 9849244 B2 US9849244 B2 US 9849244B2 US 201013320639 A US201013320639 A US 201013320639A US 9849244 B2 US9849244 B2 US 9849244B2
Authority
US
United States
Prior art keywords
dose
cartridge holder
coupling part
cartridge
setting mechanism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/320,639
Other versions
US20120172812A1 (en
Inventor
David PLUMPTRE
James Davies
Christopher Jones
Robert VEASEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to US13/320,639 priority Critical patent/US9849244B2/en
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAVIES, JAMES, JONES, CHRISTOPHER, PLUMPTRE, DAVID, VEASEY, ROBERT
Publication of US20120172812A1 publication Critical patent/US20120172812A1/en
Application granted granted Critical
Publication of US9849244B2 publication Critical patent/US9849244B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/24Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/315Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31525Dosing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/24Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2403Ampoule inserted into the ampoule holder
    • A61M2005/2407Ampoule inserted into the ampoule holder from the rear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/24Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2485Ampoule holder connected to rest of syringe
    • A61M2005/2488Ampoule holder connected to rest of syringe via rotation, e.g. threads or bayonet
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/24Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2485Ampoule holder connected to rest of syringe
    • A61M2005/2492Ampoule holder connected to rest of syringe via snap connection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/3129Syringe barrels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/3146Priming, e.g. purging, reducing backlash or clearance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/315Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533Dosing mechanisms, i.e. setting a dose
    • A61M5/31535Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
    • A61M5/31543Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/315Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533Dosing mechanisms, i.e. setting a dose
    • A61M5/31545Setting modes for dosing
    • A61M5/31548Mechanically operated dose setting member
    • A61M5/3155Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
    • A61M5/31551Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member

Definitions

  • the present patent application is generally directed to drug delivery devices. More particularly, the present patent application is generally directed to drug delivery devices, such as pen type drug delivery devices. Such devices provide for self administration of medicinal product from a multi-dose cartridge and permit a user to set the delivery dose.
  • the present application may find application in both resettable (i.e., reusable) and non-resettable (i.e., non-reusable) type drug delivery devices. However, aspects of the invention may be equally applicable in other scenarios as well.
  • Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This is increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease.
  • cartridges of medication are used. These cartridges are housed in a cartridge holder or cartridge housing. Such cartridges include a bung or stopper at one end. At the other end of the cartridge, the cartridge may comprise a pierceable seal.
  • the medication delivery device has a dose setting mechanism that uses a spindle to move in a distal direction towards the cartridge and to press a distal end of the spindle against the bung. This expels a certain set or preselected dose of medication from the cartridge. In order to insure dose accuracy, it is important that the distal end of the spindle remains on the bung of the cartridge before, during and after injection of a dose of medicament.
  • One perceived disadvantage of certain known medication delivery devices is that because of the various tolerance differences that may occur during manufacturing (e.g., tolerance differences that may arise during component molding) of the various parts making up the drug delivery device and the desire to not pre-load the bung axially in the assembled device, there may be a gap between the end of the spindle and the cartridge bung after the medication delivery device has been assembled. In other words, when initially assembled, the cartridge (and hence cartridge bung) may not be in contact with the distal end of the spindle. Therefore, if a user using the drug delivery device for the first time dials a dose, the actual dose received may be equal to the dialed dose less the initial gap between the distal end of the spindle and cartridge bung.
  • the air gap between the cartridge bung and distal end of the spindle may be equivalent to a dose that causes the received dose that is outside preferred dose accuracy limits.
  • this air gap may be equivalent to the loss of between 0 and 10 units (i.e., 0-0.14 milliliters) of drug product on the first dose.
  • a device as defined in claims 1 and 10 which requires a rotational movement of a cartridge holder to prime the device and/or to bring the device in a condition allowing setting of a dose.
  • the condition allowing setting of a dose is the primed condition of the device.
  • a drug delivery device comprises a dose setting mechanism comprising a spindle.
  • a cartridge holder is coupled to the dose setting mechanism.
  • the cartridge holder comprises a cartridge having a movable bung at one end of the cartridge.
  • the cartridge holder is rotated before a dose may be set with the dose setting mechanism.
  • the cartridge holder must be rotated less than 360 degrees before a dose may be set with the dose setting mechanism.
  • the cartridge holder must be rotated with respect to the dose setting mechanism before the dose may be set with the dose setting mechanism.
  • rotation of the cartridge holder may prime the drug delivery device.
  • rotation of the cartridge holder moves the spindle into an abutting engagement with the bung of the cartridge.
  • the cartridge holder is rotationally locked to the dose setting mechanism.
  • This rotationally locking of the cartridge holder to the dose setting mechanism may be by way of a one way, non-return detent feature.
  • the cartridge holder provides a visual indication that the cartridge holder must be rotated before the dose may be set by the dose setting mechanism.
  • the drug delivery device may either be a resettable drug delivery device or a not-resettable (disposable) drug delivery device.
  • drug or “medicinal product” or “medicament”, as used herein, mean a pharmaceutical formulation containing at least one pharmaceutically active compound
  • the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, a antibody, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
  • the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (AC S), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
  • diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (AC S), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
  • diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute
  • the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
  • the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
  • GLP-1 glucagon-like peptide
  • Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carboxy
  • Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
  • Exendin-4 derivatives are for example selected from the following list of compounds:
  • Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
  • Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Goserelin.
  • a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • Acid addition salts are e.g. HC1 or HBr salts.
  • Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
  • solvates are for example hydrates.
  • a priming mechanism for a drug delivery device comprises a dose setting mechanism.
  • the dose setting mechanism comprises a spindle and a dose dial sleeve.
  • a cartridge holder comprises a cartridge comprising a movable bung and a pierceable seal.
  • a coupling part connects the cartridge holder to the dose dial sleeve.
  • a spindle nut rotationally coupled to the coupling part, couples the cartridge holder to the spindle.
  • the coupling part which may comprise a thin metal pressing and/or a rigid coupling component, unlocks the dose dial sleeve so that the dose dial sleeve may be rotated to set a dose.
  • the dose setting mechanism comprises at least one flexible locking element.
  • the coupling part When the cartridge holder is rotated, the coupling part also rotates to thereby release said flexible locking element and allowing the dose dial sleeve to rotate and allow a user of the medical delivery device to set a dose.
  • the spindle nut may further comprise a plurality of helical ramps.
  • the plurality of helical ramps drive the spindle nut in a distal direction when the cartridge holder is rotated so that the spindle abuts a first surface of the bung.
  • FIG. 1 illustrates an arrangement of a drug delivery device in accordance with the one aspect of the present invention
  • FIG. 2 illustrates the drug delivery device of FIG. 1 with a cap removed and with a dose having been selected
  • FIG. 3 illustrates a close up view of a drug delivery device before a priming step, such as the drug delivery device illustrated in FIG. 1 ;
  • FIG. 4 illustrates a close up view of the drug delivery device illustrated in FIG. 3 after completion of a priming step
  • FIG. 5 illustrates a close up view of a connection between a dose setting mechanism and cartridge housing of a drug delivery device in a non-priming state, such as drug delivery device illustrated in FIGS. 3 and 4 ;
  • FIG. 6 illustrates a close up view of the connection between the dose setting mechanism and the cartridge illustrated in FIG. 5 , in a priming state
  • FIG. 7 illustrates a close up view of a proximal end of the cartridge housing illustrated in FIGS. 5 and 6 , including a coupling part;
  • FIG. 8 illustrates how the coupling part illustrated in FIG. 7 may be used to engage a dose dial sleeve of a dose setting mechanism, such as the dose setting mechanism illustrated in FIGS. 5 and 6 ;
  • FIG. 9 illustrates the coupling part illustrated in FIG. 8 in a non-primed state
  • FIG. 10 illustrates the coupling part illustrated in FIG. 9 in a primed state
  • FIG. 11 illustrates a close up view of the stop faces provided along the distal end of the dose dial sleeve illustrated in FIG. 10 ;
  • FIG. 12 illustrates a spindle nut that may be used to couple the coupling part to a dose setting member and to a cartridge housing;
  • FIG. 13 illustrates the spindle nut coupled to the coupling part and dose dial sleeve of a dose setting mechanism.
  • the drug delivery device 1 comprises a housing having a first cartridge retaining part 2 , and a dose setting mechanism 4 .
  • the drug delivery device may be a resettable drug delivery device (i.e., a reusable device) or alternatively a non-resettable drug delivery device (i.e., a non-reusable device).
  • a first end of the cartridge retaining part 2 and a second end of the dose setting mechanism 4 are secured together by connecting features.
  • these connecting features would be permanent and non-reversible.
  • resettable devices these connecting features would be releasable.
  • the cartridge housing 2 is secured within the second end of the dose setting mechanism 4 .
  • a removable cap 3 is releasably retained over a second end or distal end of a cartridge retaining part or cartridge housing.
  • the dose setting mechanism 4 comprises a dose dial grip 12 and a window or lens 14 .
  • a dose scale arrangement 16 is viewable through the window or lens 14 .
  • FIG. 2 illustrates the medical delivery device 1 of FIG. 1 with the cover 3 removed from a distal end 19 of the medical delivery device 1 . This removal exposes the cartridge housing 6 .
  • a cartridge 25 from which a number of doses of a medicinal product may be dispensed is provided in the cartridge housing 6 .
  • the cartridge 25 contains a type of medicament that can be administered relatively often, such as once or more times a day.
  • One such medicament is either long acting or short acting insulin or an insulin analog.
  • the cartridge 25 comprises a bung or stopper (not illustrated in FIG. 2 ) that is retained near a second end or a proximal end 33 of the cartridge 25 .
  • the medical delivery device also comprises a driver having a spindle (not illustrated in FIG. 2 ). As discussed above, before the device is primed, there may or may not be a gap between the end of the spindle and the cartridge bung.
  • the cartridge housing 6 has a distal end 23 and a proximal end 27 .
  • the cartridge distal end 23 of the cartridge housing 6 comprises a groove 8 for attaching a removable needle assembly.
  • other needle assembly connection mechanisms could also be used.
  • the drug delivery device 1 comprises a resettable device
  • the cartridge proximal end 27 is removably connected to the dose setting mechanism 4 .
  • cartridge housing proximal end 27 is removably connected to the dose setting mechanism 4 via a bayonet connection.
  • other types of removable connection methods such as threads, partial threads, ramps and detents, snap locks, snap fits, and luer locks may also be used.
  • the dose setting mechanism 4 of the drug delivery device illustrated in FIG. 2 may be utilized as a reusable drug delivery device. (i.e., a drug delivery device that can be reset) Where the drug delivery device 1 comprises a reusable drug delivery device, the cartridge 25 is removable from the cartridge housing 6 . The cartridge 25 may be removed from the device 1 without destroying the device 1 by merely having the user disconnect the dose setting mechanism 4 from the cartridge housing 6 .
  • a user can attach a suitable needle assembly to the groove 8 provided at the distal end 23 of the cartridge housing 6 .
  • a suitable needle assembly may be, for example, screwed onto a distal end 23 of the housing 6 or alternatively may be snapped onto this distal end 23 .
  • the replaceable cap 3 may be used to re-cover the cartridge housing 6 .
  • the outer dimensions of the replaceable cap 3 are similar or identical to the outer dimensions of the dose setting mechanism 4 so as to provide an impression of a unitary whole when the replaceable cap 3 is in position covering the cartridge housing 6 when the device is not in use.
  • the drug delivery device 1 preferably forces a user to prime the device before they are permitted to select the first dose.
  • the process of forcing a user to prime the cartridge before they can select and dispense the first dose reduces a potential risk of injecting the prime dose.
  • forced priming is particularly advantageous for disposable devices where there is oftentimes a gap between a distal end of the spindle and the cartridge bung before the device is used. This gap is a consequence of the tolerances associated with the assembled parts as well as the desire not to pre-load the bung axially in the assembled device.
  • the drug delivery device achieves this by the user rotating the cartridge holder relative to the housing in order to both prime the device and also to unlock the number sleeve so the user can subsequently rotate the dose dial sleeve to set the first dose.
  • the cartridge holder is locked rotationally and therefore cannot be rotated with respect to the dose setting mechanism.
  • FIG. 3 illustrates a close up view of a drug delivery device 50 before a priming step, such as the drug delivery device 1 illustrated in FIG. 1 .
  • FIG. 4 illustrates a close up view of the drug delivery device 50 illustrated in FIG. 3 after completion of a priming step.
  • the drug delivery device 50 comprises a dose setting mechanism 52 coupled to a cartridge housing 54 .
  • this coupling mechanism comprises a releasable coupling mechanism (i.e., a thread, a bayonet lock, a luer lock, a snap fit or snap lock, etc.)
  • this coupling this coupling mechanism comprises a non-reversible coupling mechanism.
  • the dose setting mechanism 52 comprises various markings and indications along an outer surface 53 .
  • this marking comprises a marking indicating a locked position (i.e., un-primed state) 58 and a marking indicating an unlocked position (i.e., primed state) 62 .
  • various intermediate markings 59 are provided between the locked and unlocked position markings 58 , 62 , respectively.
  • the cartridge housing 54 comprises markings along its outer surface 63 and these markings include a positional indicator (i.e., an arrow) 56 that is used to indicate the relative position of the cartridge housing 54 with respect to the outer surface 53 of the dose setting mechanism 52 .
  • a positional indicator i.e., an arrow
  • the cartridge housing 54 is rotated in direction of arrow 60 .
  • the cartridge housing 54 is rotated in the direction of arrow 60 with respect to the dose setting mechanism 52 so that the arrow 56 moves from the locked marking 58 and then aligns with the unlocked designation 62 , as shown in FIG. 4 .
  • the drug delivery device 50 now resides in a primed state.
  • the spindle contained in the dose setting mechanism 52 now resides adjacent or abuts the bung provided in the cartridge of the cartridge housing 54 .
  • the drug delivery device 50 is also now unlocked so that the dose setting mechanism 52 may now be used to set a dose (as illustrated in FIG. 2 ).
  • the cartridge holder 54 is also rotationally locked and can therefore no longer be rotated with respect to the dose setting mechanism 52 .
  • FIG. 5 illustrates a close up view of a connection between a dose setting mechanism and cartridge housing of a drug delivery device 70 , such as drug delivery device 50 illustrated in FIGS. 3 and 4 .
  • the drug delivery device 70 is in a pre-primed state. Therefore, with the drug delivery device illustrated in FIG. 5 , a user could not set a dose until the device is primed.
  • the dose setting mechanism 74 is rotationally coupled to the cartridge housing 72 .
  • the cartridge housing 72 comprises a rib 76 that engages with an internally formed cavity on an inner surface of the dose setting mechanism 74 .
  • This configuration allows for relative rotational movement only between the dose setting mechanism 74 and the cartridge housing 76 and no axial movement. This rotational relative movement occurs when the cartridge holder 72 is rotated from the locked position (i.e., FIG. 5 ) to the unlocked position (i.e., FIG. 6 ).
  • FIG. 7 illustrates a close up view of a proximal end 68 of the cartridge housing 72 illustrated in FIGS. 5 and 6 .
  • FIG. 7 also illustrates a coupling part 80 that may be used to couple the cartridge housing 72 to a dose setting mechanism, such as the dose setting mechanism 74 illustrated in FIGS. 5 and 6 .
  • this cartridge housing 72 comprises an L shaped cavity 73 provided along a first outer surface 75 of the cartridge housing 72 . As described with respect to FIGS. 5 and 6 and as will be described in greater detail below, this cavity 73 is used to engage a portion of a coupling part so as to allow relative rotation between the cartridge holder 72 and the dose setting mechanism.
  • coupling part 80 comprises a thin metal pressing.
  • the coupling part 80 comprises a first set of axial projecting members 82 a , 82 b that project in an axial direction towards the distal end 69 of the cartridge housing 72 . These projecting members 82 a , 82 b rotationally affix or engage a first portion 75 of the cavity 73 .
  • the coupling part 80 rotationally couples to a spindle nut and therefore a spindle of a dose setting mechanism and also acts upon a dose dial sleeve of the dose setting mechanism.
  • the coupling part 80 further comprises a second set of axial projecting members 86 a , 86 b .
  • This second set of projecting members 86 a , 86 b extend in a proximal direction away from the proximal end 68 of the cartridge housing 72 .
  • This second set of projecting members 86 a , 86 b engage a portion of the dose setting mechanism, specifically an inner housing of the dose setting mechanism.
  • the coupling part 80 further comprises two inwardly extending arms 84 a , 84 b that engage a spindle nut of the dose setting mechanism.
  • FIG. 8 illustrates how the coupling part 80 illustrated in FIG. 7 may be used to engage an inner housing 92 of a dose setting mechanism, such as the dose setting mechanism illustrated in FIGS. 5 and 6 .
  • the inner housing 92 comprises a first and a second flexible locking elements 98 a , 98 b located near a distal end 93 of the inner housing 92 .
  • a circular shaped housing portion 94 is also near this distal end 93 .
  • This housing portion 94 defines a cavity portion 101 having an inner surface and along this inner surface there are two internally radially directed recesses 96 a and 96 b.
  • the coupling part 80 will be positioned to slide into the cavity 101 of the housing portion 94 such that the second set of protruding members 86 a , 86 b of the coupling part 80 slide through recesses 96 a , 96 b of the housing portion 94 , respectively.
  • the second members 86 a , 86 b will then be positioned to reside over an external surface of the inner housing flexible elements 98 a , 98 b , respectively.
  • the drug delivery device will not be primed but rather the dose dial sleeve 103 will be locked out and prevented from rotating.
  • a user of such a drug delivery device will be prevented from selecting a dose, that is, the user will be prevented from rotating the dose dial sleeve 103 before the user has under taken a drug delivery device priming step.
  • FIG. 9 illustrates the coupling part 80 engaged with the distal end 93 of the inner housing 92 .
  • the coupling part 80 is in an initial position or in a non-primed state, before device priming occurs.
  • the set of protruding elements 86 a , 86 b reside over the surface of the flexible elements 98 a , and 98 b , respectively. Therefore, when a cartridge holder is connected to the housing and is rotated (as illustrated in FIGS. 4 and 5 ), the coupling part 80 also rotates.
  • FIG. 10 illustrates the coupling part 80 and inner housing 92 after rotating the coupling part to release the flexible locking elements and thereby completing of the priming step.
  • the coupling part 80 has been rotated to a final or stop position 102 and the coupling part 80 has now been is rotated less than 360 degrees so as to push the inner housing flexible elements 98 a , 98 b radially inward.
  • FIG. 11 illustrates a close up view of the stop faces 106 a , 106 b provided along the distal end of the inner housing 92 .
  • the dose dial sleeve 103 is also illustrated with a scale arrangement 104 provided along an outer surface of this dose dial sleeve 103 .
  • the dose dial sleeve 103 has mating stop faces 97 a , 97 b that engage with stop faces 106 a , 106 b on the inner housing.
  • a spindle nut 114 is coupled to the coupling part 80 so that when the coupling part 80 rotates the spindle nut 114 rotates to drive a spindle 124 distally.
  • this spindle nut 114 is circular in shape and comprises a first and a second helical ramp 116 a , 116 b .
  • the spindle nut 114 further comprises a circular cavity having a male groove member 118 .
  • the first and second helical ramps 116 a , 116 b serve to drive the spindle nut 114 in a distal direction (i.e., towards the injection site) when the cartridge holder is rotated.
  • these helical ramps lock the cartridge holder rotationally at the end of the priming step.
  • the helical ramps are detented so as to allow the cartridge housing 72 to be rotated back and removed to enable a new cartridge to be fitted.
  • the height of the helical ramps 116 a , 116 b help to offset any slack in the drive mechanism that drives the spindle of the dose setting mechanism forwards to dispense a dose. In this manner, rotating the cartridge holder is generally equivalent to pressing on a dose button of the dose setting mechanism so as to take up slack in the drive mechanism.
  • FIG. 13 illustrates the spindle nut 114 coupled to the coupling part 80 and inner housing 92 of a dose setting mechanism.
  • the coupling part 80 is rotated by the cartridge holder (not illustrated). This in turn rotates the spindle nut 114 .
  • this spindle has at least two overlapping grooves.
  • one of these grooves 130 is engaged with a portion of the drug delivery device and could be either helical or axially extending along its length.
  • the spindle 124 is threaded to a portion of the drug delivery device, as the spindle nut 114 rotates, it advances the spindle 124 axially in the distal direction D 2 128 so as to prime the drug delivery device.
  • the rotation of the cartridge housing also unlocks the dose dial sleeve 103 to allow a user to now set a first dose of medication for the drug delivery device.

Abstract

A drug delivery device is provided comprising a dose setting mechanism having a spindle and a cartridge holder coupled to the dose setting mechanism. The cartridge holder comprising a cartridge having a movable bung at one end of the cartridge. The cartridge holder must be rotated before a dose may set with the dose setting mechanism.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a U.S. National Phase Application pursuant to 35 U.S.C. §371 of International Application No. PCT/EP2010/057473 filed May 28, 2010, which claims priority to U.S. Provisional Patent Application No. 61/182,828 filed on Jun. 1, 2009 and European Patent Application No. 09009052.3 filed on Jul. 10, 2009. The entire disclosure contents of these applications are herewith incorporated by reference into the present application.
FIELD OF THE INVENTION
The present patent application is generally directed to drug delivery devices. More particularly, the present patent application is generally directed to drug delivery devices, such as pen type drug delivery devices. Such devices provide for self administration of medicinal product from a multi-dose cartridge and permit a user to set the delivery dose. The present application may find application in both resettable (i.e., reusable) and non-resettable (i.e., non-reusable) type drug delivery devices. However, aspects of the invention may be equally applicable in other scenarios as well.
BACKGROUND
Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This is increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease.
In certain types of medication delivery devices, such as pen type devices, cartridges of medication are used. These cartridges are housed in a cartridge holder or cartridge housing. Such cartridges include a bung or stopper at one end. At the other end of the cartridge, the cartridge may comprise a pierceable seal. To dispense a dose of medication from such a cartridge, the medication delivery device has a dose setting mechanism that uses a spindle to move in a distal direction towards the cartridge and to press a distal end of the spindle against the bung. This expels a certain set or preselected dose of medication from the cartridge. In order to insure dose accuracy, it is important that the distal end of the spindle remains on the bung of the cartridge before, during and after injection of a dose of medicament.
One perceived disadvantage of certain known medication delivery devices is that because of the various tolerance differences that may occur during manufacturing (e.g., tolerance differences that may arise during component molding) of the various parts making up the drug delivery device and the desire to not pre-load the bung axially in the assembled device, there may be a gap between the end of the spindle and the cartridge bung after the medication delivery device has been assembled. In other words, when initially assembled, the cartridge (and hence cartridge bung) may not be in contact with the distal end of the spindle. Therefore, if a user using the drug delivery device for the first time dials a dose, the actual dose received may be equal to the dialed dose less the initial gap between the distal end of the spindle and cartridge bung. The air gap between the cartridge bung and distal end of the spindle may be equivalent to a dose that causes the received dose that is outside preferred dose accuracy limits. For example, this air gap may be equivalent to the loss of between 0 and 10 units (i.e., 0-0.14 milliliters) of drug product on the first dose.
There is, therefore, a general need to take these perceived issues into consideration when designing either resettable or non-resettable drug delivery devices, such as pen type drug delivery devices.
SUMMARY
It is an object of the present invention to provide an improved dose setting mechanism which is especially suitable for priming a drug delivery device and/or prevents use of the device prior to a priming step.
This object is solved by a device as defined in claims 1 and 10 which requires a rotational movement of a cartridge holder to prime the device and/or to bring the device in a condition allowing setting of a dose. Preferably, the condition allowing setting of a dose is the primed condition of the device.
According to a first embodiment, a drug delivery device comprises a dose setting mechanism comprising a spindle. A cartridge holder is coupled to the dose setting mechanism. The cartridge holder comprises a cartridge having a movable bung at one end of the cartridge. The cartridge holder is rotated before a dose may be set with the dose setting mechanism. Preferably, the cartridge holder must be rotated less than 360 degrees before a dose may be set with the dose setting mechanism.
In more detail, the cartridge holder must be rotated with respect to the dose setting mechanism before the dose may be set with the dose setting mechanism. Thus, rotation of the cartridge holder may prime the drug delivery device.
According to a preferred development of this embodiment, rotation of the cartridge holder moves the spindle into an abutting engagement with the bung of the cartridge.
It may be advantageous, if rotation of the cartridge holder enables a dose dial sleeve of the dose setting mechanism to rotate which allows a user of the dose setting mechanism to set the dose.
Preferably, after the cartridge holder is rotated, the cartridge holder is rotationally locked to the dose setting mechanism. This rotationally locking of the cartridge holder to the dose setting mechanism may be by way of a one way, non-return detent feature.
To facilitate use of the device, the cartridge holder provides a visual indication that the cartridge holder must be rotated before the dose may be set by the dose setting mechanism.
According to the present invention, the drug delivery device may either be a resettable drug delivery device or a not-resettable (disposable) drug delivery device.
The terms “drug” or “medicinal product” or “medicament”, as used herein, mean a pharmaceutical formulation containing at least one pharmaceutically active compound,
wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, a antibody, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (AC S), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.
Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.
Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
Exendin-4 derivatives are for example selected from the following list of compounds:
H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
des Pro36 [Asp28] Exendin-4(1-39),
des Pro36 [IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39); or
des Pro36 [Asp28] Exendin-4(1-39),
des Pro36 [IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),
wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
or an Exendin-4 derivative of the sequence
H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
H-(Lys)6-desPro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25] Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;
or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exedin-4 derivative.
Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HC1 or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.
Pharmaceutically acceptable solvates are for example hydrates.
According to another embodiment of the present invention, a priming mechanism for a drug delivery device comprises a dose setting mechanism. The dose setting mechanism comprises a spindle and a dose dial sleeve. A cartridge holder comprises a cartridge comprising a movable bung and a pierceable seal. A coupling part connects the cartridge holder to the dose dial sleeve. A spindle nut, rotationally coupled to the coupling part, couples the cartridge holder to the spindle. When the cartridge holder is rotated with respect to the dose setting mechanism, the spindle nut is rotated and the coupling part moves the spindle into an abutting engagement with the bung. Thus, priming of the device is effected by a rotation of the cartridge holder.
In the priming mechanism the coupling part, which may comprise a thin metal pressing and/or a rigid coupling component, unlocks the dose dial sleeve so that the dose dial sleeve may be rotated to set a dose.
Preferably, the dose setting mechanism comprises at least one flexible locking element. When the cartridge holder is rotated, the coupling part also rotates to thereby release said flexible locking element and allowing the dose dial sleeve to rotate and allow a user of the medical delivery device to set a dose.
The spindle nut may further comprise a plurality of helical ramps. The plurality of helical ramps drive the spindle nut in a distal direction when the cartridge holder is rotated so that the spindle abuts a first surface of the bung.
These as well as other advantages of various aspects of the present invention will become apparent to those of ordinary skill in the art by reading the following detailed description, with appropriate reference to the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Exemplary embodiments are described herein with reference to the drawings, in which:
FIG. 1 illustrates an arrangement of a drug delivery device in accordance with the one aspect of the present invention;
FIG. 2 illustrates the drug delivery device of FIG. 1 with a cap removed and with a dose having been selected;
FIG. 3 illustrates a close up view of a drug delivery device before a priming step, such as the drug delivery device illustrated in FIG. 1;
FIG. 4 illustrates a close up view of the drug delivery device illustrated in FIG. 3 after completion of a priming step;
FIG. 5 illustrates a close up view of a connection between a dose setting mechanism and cartridge housing of a drug delivery device in a non-priming state, such as drug delivery device illustrated in FIGS. 3 and 4;
FIG. 6 illustrates a close up view of the connection between the dose setting mechanism and the cartridge illustrated in FIG. 5, in a priming state;
FIG. 7 illustrates a close up view of a proximal end of the cartridge housing illustrated in FIGS. 5 and 6, including a coupling part;
FIG. 8 illustrates how the coupling part illustrated in FIG. 7 may be used to engage a dose dial sleeve of a dose setting mechanism, such as the dose setting mechanism illustrated in FIGS. 5 and 6;
FIG. 9 illustrates the coupling part illustrated in FIG. 8 in a non-primed state;
FIG. 10 illustrates the coupling part illustrated in FIG. 9 in a primed state;
FIG. 11 illustrates a close up view of the stop faces provided along the distal end of the dose dial sleeve illustrated in FIG. 10;
FIG. 12 illustrates a spindle nut that may be used to couple the coupling part to a dose setting member and to a cartridge housing; and
FIG. 13 illustrates the spindle nut coupled to the coupling part and dose dial sleeve of a dose setting mechanism.
DETAILED DESCRIPTION
Referring to FIG. 1, there is shown a drug delivery device 1 in accordance with an exemplary arrangement. The drug delivery device 1 comprises a housing having a first cartridge retaining part 2, and a dose setting mechanism 4. The drug delivery device may be a resettable drug delivery device (i.e., a reusable device) or alternatively a non-resettable drug delivery device (i.e., a non-reusable device). A first end of the cartridge retaining part 2 and a second end of the dose setting mechanism 4 are secured together by connecting features. For non-resettable devices, these connecting features would be permanent and non-reversible. For resettable devices, these connecting features would be releasable.
In this illustrated arrangement, the cartridge housing 2 is secured within the second end of the dose setting mechanism 4. A removable cap 3 is releasably retained over a second end or distal end of a cartridge retaining part or cartridge housing. The dose setting mechanism 4 comprises a dose dial grip 12 and a window or lens 14. A dose scale arrangement 16 is viewable through the window or lens 14. To set a dose of medication contained within the drug delivery device 1, a user rotates the dose dial grip 12 such that a dialed dose will become viewable in the window or lens 14 by way of the dose scale arrangement 16.
FIG. 2 illustrates the medical delivery device 1 of FIG. 1 with the cover 3 removed from a distal end 19 of the medical delivery device 1. This removal exposes the cartridge housing 6. As illustrated, a cartridge 25 from which a number of doses of a medicinal product may be dispensed, is provided in the cartridge housing 6. Preferably, the cartridge 25 contains a type of medicament that can be administered relatively often, such as once or more times a day. One such medicament is either long acting or short acting insulin or an insulin analog. The cartridge 25 comprises a bung or stopper (not illustrated in FIG. 2) that is retained near a second end or a proximal end 33 of the cartridge 25. The medical delivery device also comprises a driver having a spindle (not illustrated in FIG. 2). As discussed above, before the device is primed, there may or may not be a gap between the end of the spindle and the cartridge bung.
The cartridge housing 6 has a distal end 23 and a proximal end 27. Preferably, the cartridge distal end 23 of the cartridge housing 6 comprises a groove 8 for attaching a removable needle assembly. However, other needle assembly connection mechanisms could also be used. If the drug delivery device 1 comprises a resettable device, the cartridge proximal end 27 is removably connected to the dose setting mechanism 4. In one preferred embodiment, cartridge housing proximal end 27 is removably connected to the dose setting mechanism 4 via a bayonet connection. However, as those of ordinary skill in the art will recognize, other types of removable connection methods such as threads, partial threads, ramps and detents, snap locks, snap fits, and luer locks may also be used.
As previously mentioned, the dose setting mechanism 4 of the drug delivery device illustrated in FIG. 2 may be utilized as a reusable drug delivery device. (i.e., a drug delivery device that can be reset) Where the drug delivery device 1 comprises a reusable drug delivery device, the cartridge 25 is removable from the cartridge housing 6. The cartridge 25 may be removed from the device 1 without destroying the device 1 by merely having the user disconnect the dose setting mechanism 4 from the cartridge housing 6.
In use, once the cap 3 is removed, a user can attach a suitable needle assembly to the groove 8 provided at the distal end 23 of the cartridge housing 6. Such needle assembly may be, for example, screwed onto a distal end 23 of the housing 6 or alternatively may be snapped onto this distal end 23. After use, the replaceable cap 3 may be used to re-cover the cartridge housing 6. Preferably, the outer dimensions of the replaceable cap 3 are similar or identical to the outer dimensions of the dose setting mechanism 4 so as to provide an impression of a unitary whole when the replaceable cap 3 is in position covering the cartridge housing 6 when the device is not in use.
In accordance with an exemplary arrangement, it may be beneficial to force a user to prime the drug delivery device of FIGS. 1 and 2 before the user dials and injects the first dose. In order to achieve this forced priming, as will be discussed in greater detail below, the drug delivery device 1 preferably forces a user to prime the device before they are permitted to select the first dose.
The process of forcing a user to prime the cartridge before they can select and dispense the first dose reduces a potential risk of injecting the prime dose. The idea of forced priming is particularly advantageous for disposable devices where there is oftentimes a gap between a distal end of the spindle and the cartridge bung before the device is used. This gap is a consequence of the tolerances associated with the assembled parts as well as the desire not to pre-load the bung axially in the assembled device.
If the device is designed so that this gap between a distal end of the spindle and the bung is removed (i.e., the device primed) before the user is able to dial a dose, then this is advantageous. In one preferred arrangement, the drug delivery device achieves this by the user rotating the cartridge holder relative to the housing in order to both prime the device and also to unlock the number sleeve so the user can subsequently rotate the dose dial sleeve to set the first dose. Preferably, once the device has been primed, the cartridge holder is locked rotationally and therefore cannot be rotated with respect to the dose setting mechanism.
FIG. 3 illustrates a close up view of a drug delivery device 50 before a priming step, such as the drug delivery device 1 illustrated in FIG. 1. FIG. 4 illustrates a close up view of the drug delivery device 50 illustrated in FIG. 3 after completion of a priming step. As illustrated, the drug delivery device 50 comprises a dose setting mechanism 52 coupled to a cartridge housing 54. Where the drug delivery device 50 comprises a re-settable drug delivery device, this coupling mechanism comprises a releasable coupling mechanism (i.e., a thread, a bayonet lock, a luer lock, a snap fit or snap lock, etc.) Where the drug delivery device 50 comprises a non-resettable drug delivery device (i.e., a disposable drug delivery device), this coupling this coupling mechanism comprises a non-reversible coupling mechanism.
In this preferred arrangement of drug delivery device 50, the dose setting mechanism 52 comprises various markings and indications along an outer surface 53. As can be seen in this arrangement, this marking comprises a marking indicating a locked position (i.e., un-primed state) 58 and a marking indicating an unlocked position (i.e., primed state) 62. In addition, various intermediate markings 59 are provided between the locked and unlocked position markings 58, 62, respectively.
In addition, the cartridge housing 54 comprises markings along its outer surface 63 and these markings include a positional indicator (i.e., an arrow) 56 that is used to indicate the relative position of the cartridge housing 54 with respect to the outer surface 53 of the dose setting mechanism 52. In this preferred arrangement, to prime the drug delivery device 50, the cartridge housing 54 is rotated in direction of arrow 60. Preferably, the cartridge housing 54 is rotated in the direction of arrow 60 with respect to the dose setting mechanism 52 so that the arrow 56 moves from the locked marking 58 and then aligns with the unlocked designation 62, as shown in FIG. 4. In this final position, the drug delivery device 50 now resides in a primed state. That is, the spindle contained in the dose setting mechanism 52 now resides adjacent or abuts the bung provided in the cartridge of the cartridge housing 54. In addition, in a preferred arrangement, the drug delivery device 50 is also now unlocked so that the dose setting mechanism 52 may now be used to set a dose (as illustrated in FIG. 2). Most preferably, in this final position, the cartridge holder 54 is also rotationally locked and can therefore no longer be rotated with respect to the dose setting mechanism 52.
FIG. 5 illustrates a close up view of a connection between a dose setting mechanism and cartridge housing of a drug delivery device 70, such as drug delivery device 50 illustrated in FIGS. 3 and 4. In FIG. 5, the drug delivery device 70 is in a pre-primed state. Therefore, with the drug delivery device illustrated in FIG. 5, a user could not set a dose until the device is primed. As illustrated, the dose setting mechanism 74 is rotationally coupled to the cartridge housing 72. In this arrangement, the cartridge housing 72 comprises a rib 76 that engages with an internally formed cavity on an inner surface of the dose setting mechanism 74. This configuration allows for relative rotational movement only between the dose setting mechanism 74 and the cartridge housing 76 and no axial movement. This rotational relative movement occurs when the cartridge holder 72 is rotated from the locked position (i.e., FIG. 5) to the unlocked position (i.e., FIG. 6).
FIG. 7 illustrates a close up view of a proximal end 68 of the cartridge housing 72 illustrated in FIGS. 5 and 6. FIG. 7 also illustrates a coupling part 80 that may be used to couple the cartridge housing 72 to a dose setting mechanism, such as the dose setting mechanism 74 illustrated in FIGS. 5 and 6. In this preferred arrangement, this cartridge housing 72 comprises an L shaped cavity 73 provided along a first outer surface 75 of the cartridge housing 72. As described with respect to FIGS. 5 and 6 and as will be described in greater detail below, this cavity 73 is used to engage a portion of a coupling part so as to allow relative rotation between the cartridge holder 72 and the dose setting mechanism.
In this preferred arrangement, coupling part 80 comprises a thin metal pressing. However, those of ordinary skill will recognize that alternative coupling part arrangements may also be used. In this preferred arrangement, the coupling part 80 comprises a first set of axial projecting members 82 a, 82 b that project in an axial direction towards the distal end 69 of the cartridge housing 72. These projecting members 82 a, 82 b rotationally affix or engage a first portion 75 of the cavity 73. In addition, the coupling part 80 rotationally couples to a spindle nut and therefore a spindle of a dose setting mechanism and also acts upon a dose dial sleeve of the dose setting mechanism.
The coupling part 80 further comprises a second set of axial projecting members 86 a, 86 b. This second set of projecting members 86 a, 86 b extend in a proximal direction away from the proximal end 68 of the cartridge housing 72. This second set of projecting members 86 a, 86 b engage a portion of the dose setting mechanism, specifically an inner housing of the dose setting mechanism. As described below, the coupling part 80 further comprises two inwardly extending arms 84 a, 84 b that engage a spindle nut of the dose setting mechanism.
FIG. 8 illustrates how the coupling part 80 illustrated in FIG. 7 may be used to engage an inner housing 92 of a dose setting mechanism, such as the dose setting mechanism illustrated in FIGS. 5 and 6. As illustrated, the inner housing 92 comprises a first and a second flexible locking elements 98 a, 98 b located near a distal end 93 of the inner housing 92. Also near this distal end 93 is a circular shaped housing portion 94. This housing portion 94 defines a cavity portion 101 having an inner surface and along this inner surface there are two internally radially directed recesses 96 a and 96 b.
During assembly, the coupling part 80 will be positioned to slide into the cavity 101 of the housing portion 94 such that the second set of protruding members 86 a, 86 b of the coupling part 80 slide through recesses 96 a, 96 b of the housing portion 94, respectively. The second members 86 a, 86 b will then be positioned to reside over an external surface of the inner housing flexible elements 98 a, 98 b, respectively. In this position, the drug delivery device will not be primed but rather the dose dial sleeve 103 will be locked out and prevented from rotating. As such, a user of such a drug delivery device will be prevented from selecting a dose, that is, the user will be prevented from rotating the dose dial sleeve 103 before the user has under taken a drug delivery device priming step.
FIG. 9 illustrates the coupling part 80 engaged with the distal end 93 of the inner housing 92. As illustrated, the coupling part 80 is in an initial position or in a non-primed state, before device priming occurs. In this initial position, the set of protruding elements 86 a, 86 b reside over the surface of the flexible elements 98 a, and 98 b, respectively. Therefore, when a cartridge holder is connected to the housing and is rotated (as illustrated in FIGS. 4 and 5), the coupling part 80 also rotates. As the coupling part 80 is rotated in the direction of arrow D1, the first set of protruding elements 86 a, 86 b rotate over the flexible locking elements 98 a, 98 b and end up releasing these flexible locking elements, and therefore stop faces 106 a, 106 b from the dose dial sleeve. FIG. 10 illustrates the coupling part 80 and inner housing 92 after rotating the coupling part to release the flexible locking elements and thereby completing of the priming step. As illustrated, the coupling part 80 has been rotated to a final or stop position 102 and the coupling part 80 has now been is rotated less than 360 degrees so as to push the inner housing flexible elements 98 a, 98 b radially inward. This releases the inner housing stop faces 106 a, 106 b, from the dose dial sleeve 103. FIG. 11 illustrates a close up view of the stop faces 106 a, 106 b provided along the distal end of the inner housing 92. The dose dial sleeve 103 is also illustrated with a scale arrangement 104 provided along an outer surface of this dose dial sleeve 103. The dose dial sleeve 103 has mating stop faces 97 a, 97 b that engage with stop faces 106 a, 106 b on the inner housing.
A spindle nut 114 is coupled to the coupling part 80 so that when the coupling part 80 rotates the spindle nut 114 rotates to drive a spindle 124 distally. As illustrated, this spindle nut 114 is circular in shape and comprises a first and a second helical ramp 116 a, 116 b. The spindle nut 114 further comprises a circular cavity having a male groove member 118. Once assembled, the spindle nut 114 is rotationally coupled to the coupling part 80 so that when a cartridge holder is coupled to a dose setting member and the cartridge holder is rotated, the spindle nut 114 rotates along with the cartridge holder. The first and second helical ramps 116 a, 116 b serve to drive the spindle nut 114 in a distal direction (i.e., towards the injection site) when the cartridge holder is rotated. Where the spindle nut 114 is used in a non-resettable drug delivery device, these helical ramps lock the cartridge holder rotationally at the end of the priming step. However, where the spindle nut is used in a resettable drug delivery device, the helical ramps are detented so as to allow the cartridge housing 72 to be rotated back and removed to enable a new cartridge to be fitted.
The height of the helical ramps 116 a, 116 b help to offset any slack in the drive mechanism that drives the spindle of the dose setting mechanism forwards to dispense a dose. In this manner, rotating the cartridge holder is generally equivalent to pressing on a dose button of the dose setting mechanism so as to take up slack in the drive mechanism.
FIG. 13 illustrates the spindle nut 114 coupled to the coupling part 80 and inner housing 92 of a dose setting mechanism. In this illustration, the coupling part 80 is rotated by the cartridge holder (not illustrated). This in turn rotates the spindle nut 114. As illustrated, this spindle has at least two overlapping grooves. Preferably, one of these grooves 130 is engaged with a portion of the drug delivery device and could be either helical or axially extending along its length.
Because in one arrangement the spindle 124 is threaded to a portion of the drug delivery device, as the spindle nut 114 rotates, it advances the spindle 124 axially in the distal direction D2 128 so as to prime the drug delivery device. The rotation of the cartridge housing, as mentioned, also unlocks the dose dial sleeve 103 to allow a user to now set a first dose of medication for the drug delivery device.
Exemplary embodiments of the present invention have been described. Those skilled in the art will understand, however, that changes and modifications may be made to these embodiments without departing from the true scope and spirit of the present invention, which is defined by the claims.

Claims (5)

The invention claimed is:
1. A priming mechanism for a drug delivery device said priming mechanism comprising:
a dose setting mechanism comprising a housing, spindle, a dose dial sleeve and at least one flexible locking element configured to engage with and lock out the dose dial sleeve to prevent it from rotating relative to the housing before the drug delivery device has been primed;
a cartridge holder, said cartridge holder comprising a cartridge, said cartridge comprising a movable bung near a proximal end of said cartridge;
a coupling part separate from either the cartridge holder or the dose setting mechanism and configured to engage and connect the cartridge holder to the dose setting mechanism such that the coupling part and cartridge holder are rotatably fixed to each other, the coupling part having at least one inwardly extending arm, where the coupling part is configured to be movable relative to the dose dial sleeve from an initial non-primed state,
a spindle nut separate from either the cartridge holder or the dose setting mechanism where the spindle nut is rotationally fixed to said coupling part through engagement with the at least one inwardly extending arm, said spindle nut is rotationally engaged with the spindle, where the coupling part, spindle nut and cartridge holder are rotationally fixed to each other so that the spindle nut and cartridge holder can rotate relative to the spindle when the cartridge holder is engage with the coupling part;
such that priming of the drug delivery device is initiated when said cartridge holder is rotated with respect to said dose setting mechanism, where the rotation of the cartridge holder causes the spindle nut to rotate with the cartridge holder relative to the spindle and relative to the dose setting mechanism thereby driving the spindle to move axially without rotation into an abutting engagement with said bung; and
where rotation of the cartridge holder relative to the dose setting mechanism rotates the coupling part relative to the at least one flexible locking element which releases the at least one flexible locking element from engagement with the dose dial sleeve allowing said dose dial sleeve to rotate and allowing a user of said medical delivery device to set a dose.
2. The priming mechanism of claim 1 wherein said coupling part unlocks said dose dial sleeve so that said dose dial sleeve may be rotated to set a dose.
3. The priming mechanism of claim 1 wherein said coupling part comprises a thin metal pressing.
4. The priming mechanism of claim 1 wherein said coupling part comprises a rigid coupling component.
5. The priming mechanism of claim 1 wherein said spindle nut further comprises a plurality of helical ramps, said plurality of helical ramps driving said spindle nut in a distal direction when said cartridge holder is rotated so that said spindle abuts a first surface of said bung.
US13/320,639 2009-06-01 2010-05-28 Dose setting mechanism for priming a drug delivery device Active 2032-01-28 US9849244B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/320,639 US9849244B2 (en) 2009-06-01 2010-05-28 Dose setting mechanism for priming a drug delivery device

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18282809P 2009-06-01 2009-06-01
EP09009052 2009-07-10
EP09009052 2009-07-10
EP09009052.3 2009-07-10
PCT/EP2010/057473 WO2010139634A1 (en) 2009-06-01 2010-05-28 Dose setting mechanism for priming a drug delivery device
US13/320,639 US9849244B2 (en) 2009-06-01 2010-05-28 Dose setting mechanism for priming a drug delivery device

Publications (2)

Publication Number Publication Date
US20120172812A1 US20120172812A1 (en) 2012-07-05
US9849244B2 true US9849244B2 (en) 2017-12-26

Family

ID=42244292

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/788,683 Active 2033-02-14 US9950116B2 (en) 2009-06-01 2010-05-27 Dose setting mechanism for priming a drug delivery device
US13/320,639 Active 2032-01-28 US9849244B2 (en) 2009-06-01 2010-05-28 Dose setting mechanism for priming a drug delivery device
US15/926,400 Active 2032-07-07 US11471602B2 (en) 2009-06-01 2018-03-20 Dose setting mechanism for priming a drug delivery device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/788,683 Active 2033-02-14 US9950116B2 (en) 2009-06-01 2010-05-27 Dose setting mechanism for priming a drug delivery device

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/926,400 Active 2032-07-07 US11471602B2 (en) 2009-06-01 2018-03-20 Dose setting mechanism for priming a drug delivery device

Country Status (10)

Country Link
US (3) US9950116B2 (en)
EP (1) EP2437812B1 (en)
JP (1) JP5690335B2 (en)
CN (1) CN102448518B (en)
AU (1) AU2010255809B2 (en)
BR (1) BRPI1014730A2 (en)
CA (1) CA2762425A1 (en)
DK (1) DK2437812T3 (en)
IL (1) IL216481A (en)
WO (1) WO2010139634A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433186B2 (en) 2017-12-13 2022-09-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11439758B2 (en) 2019-06-05 2022-09-13 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068290A2 (en) 2002-02-11 2003-08-21 Antares Pharma, Inc. Intradermal injector
EP3495009B1 (en) 2005-01-24 2021-12-08 Antares Pharma, Inc. An injector with prefilled syringe
WO2007131025A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Injector with adjustable dosing
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
CA2718053C (en) 2008-03-10 2016-09-27 Antares Pharma, Inc. Injector safety device
JP5611208B2 (en) 2008-08-05 2014-10-22 アンタレス・ファーマ・インコーポレーテッド Multiple dose injection device
US8579865B2 (en) 2009-03-20 2013-11-12 Antares Pharma, Inc. Hazardous agent injection system
US9950116B2 (en) * 2009-06-01 2018-04-24 Sanofi-Aventis Deutschland Gmbh Dose setting mechanism for priming a drug delivery device
EP2292286A1 (en) * 2009-09-07 2011-03-09 Sanofi-Aventis Deutschland GmbH Drive mechanism for a medication delivery device and medication delivery device
EP2475411B1 (en) * 2009-09-07 2014-12-31 Sanofi-Aventis Deutschland GmbH Drive mechanism for drug delivery device
EP2482889B1 (en) * 2009-09-30 2016-02-10 Sanofi-Aventis Deutschland GmbH Assembly for a drug delivery device
CA2773011A1 (en) * 2009-09-30 2011-04-07 Sanofi-Aventis Deutschland Gmbh Drug delivery device and drive member for a drug delivery device
AR078457A1 (en) * 2009-09-30 2011-11-09 Sanofi Aventis Deutschland DRIVING MECHANISM FOR A DRUG DISCHARGE DEVICE
US9402960B2 (en) * 2009-09-30 2016-08-02 Sanofi-Aventis Deutschland Gmbh Drive mechanism for a drug delivery device and use of a reset member for a drive mechanism
TWI464002B (en) * 2010-11-08 2014-12-11 Shl Group Ab Container holder assembly and medicament delivery device assembly
WO2012127046A2 (en) 2011-03-24 2012-09-27 Sanofi-Aventis Deutschland Gmbh Device and method for detecting an actuation action performable with a medical device
CA2830002C (en) * 2011-03-25 2019-03-19 Sanofi-Aventis Deutschland Gmbh Drug delivery device
KR20140050010A (en) * 2011-06-17 2014-04-28 사노피-아벤티스 도이칠란트 게엠베하 Cartridge holder assembly for drug delivery devices
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
CN104582760A (en) * 2012-01-25 2015-04-29 诺沃—诺迪斯克有限公司 Drug delivery device with cartridge fixation feature
EP2817042A1 (en) 2012-02-24 2014-12-31 Novo Nordisk A/S Drug delivery device with cartridge snap holding feature
KR20150003179A (en) 2012-03-06 2015-01-08 안타레스 팔마, 인코퍼레이티드 Prefilled syringe with breakaway force feature
CN104519928B (en) 2012-04-05 2017-09-22 赛诺菲-安万特德国有限公司 pen-type injector
CN104487114A (en) 2012-04-06 2015-04-01 安塔雷斯药品公司 Needle assisted jet injection administration of testosterone compositions
RU2724011C1 (en) 2012-04-13 2020-06-18 Бектон, Дикинсон Энд Компани Automated device for injections
US9364610B2 (en) 2012-05-07 2016-06-14 Antares Pharma, Inc. Injection device with cammed ram assembly
DK2953667T3 (en) 2013-02-11 2020-01-27 Antares Pharma Inc Needle-assisted jet injection device with reduced triggering power
EP2968792B1 (en) 2013-03-11 2019-05-15 Antares Pharma, Inc. Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
AU2014296217B2 (en) 2013-08-02 2018-08-30 Becton, Dickinson And Company Injection pen
EP3058970A1 (en) * 2015-02-19 2016-08-24 Sanofi-Aventis Deutschland GmbH Data collection device for attachment to an injection device
EP4316552A2 (en) 2015-06-09 2024-02-07 Sanofi-Aventis Deutschland GmbH Data collection apparatus for attachment to an injection device
CN107787234B (en) 2015-07-01 2021-03-12 诺和诺德股份有限公司 Piston washer for a drug delivery device and drug delivery device incorporating such a piston washer
CN107708773B (en) 2015-07-01 2020-10-30 诺和诺德股份有限公司 Drug delivery device and method for assembling a drug delivery device
JP7230527B2 (en) * 2019-01-22 2023-03-01 京セラドキュメントソリューションズ株式会社 Toner container and image forming apparatus

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533575A (en) 1895-02-05 wilkens
US5092842A (en) * 1987-05-08 1992-03-03 Wilhelm Haselmeier Gmbh & Co. Injection device with a cocking element and a second setting element
US5226895A (en) * 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5279586A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Reusable medication delivery pen
US5304152A (en) 1990-03-29 1994-04-19 Bernard Sams Dispensing device
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
US5480387A (en) 1991-07-24 1996-01-02 Medico Development Investment Company Injection device
US5505704A (en) 1993-04-02 1996-04-09 Eli Lilly And Company Manifold medication injection apparatus and method
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
WO1997010864A1 (en) 1995-09-19 1997-03-27 Becton Dickinson And Company Pen injector with cartridge loading mechanism
US5626566A (en) 1991-10-18 1997-05-06 Novo Nordisk A/S Large dose pen
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
US5921966A (en) 1997-08-11 1999-07-13 Becton Dickinson And Company Medication delivery pen having an improved clutch assembly
WO1999038554A1 (en) 1998-01-30 1999-08-05 Novo Nordisk A/S An injection syringe
EP0937472A2 (en) 1998-02-20 1999-08-25 Becton Dickinson and Company Repeat-dose medication delivery pen
EP0937471A2 (en) 1998-02-20 1999-08-25 Becton Dickinson and Company Medication delivery pen
EP0937476A2 (en) 1998-02-23 1999-08-25 Becton, Dickinson and Company Low-cost medication delivery pen
WO2001010484A1 (en) 1999-08-05 2001-02-15 Becton, Dickinson And Company Medication delivery pen
US6193698B1 (en) 1997-07-18 2001-02-27 Disetronic Licensing Ag System for locking a dosing button in a device for the adminstration of a product to be injected
US6221046B1 (en) 1995-03-07 2001-04-24 Eli Lilly And Company Recyclable medication dispensing device
US20020052578A1 (en) 2000-06-16 2002-05-02 Moller Claus Schmidt Injection device
US20020120235A1 (en) 2001-01-05 2002-08-29 Christian Enggaard Automatic injection device with reset feature
US20030050609A1 (en) 2000-03-24 2003-03-13 Bernard Sams One-way clutch mechanisms and injector devices
US20040210199A1 (en) 2001-05-16 2004-10-21 Atterbury William Goodwin Medication injector apparatus with drive assembly that facilitates reset
US20040267207A1 (en) 2003-03-03 2004-12-30 Veasey Robert Frederick Drive mechanisms suitable for use in drug delivery devices
EP1541185A1 (en) 2003-12-08 2005-06-15 Novo Nordisk A/S Automatic syringe with priming mechanism
US20060153693A1 (en) 2004-12-31 2006-07-13 Patrick Fiechter Administering apparatus comprising a service life timer
US20070016142A1 (en) * 2005-05-24 2007-01-18 Stefan Burren Dose metering mechanism for an injection device
US20080027397A1 (en) * 2003-08-12 2008-01-31 Deruntz Otto D Medication dispensing apparatus with triple screw threads for mechanical advantage
WO2008074897A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S A syringe device
US20080183139A1 (en) * 2005-05-24 2008-07-31 Stefan Burren Dose setting mechanism for an injection device
US20090275916A1 (en) 2008-05-02 2009-11-05 Sanofi-Aventis Deutschland Gmbh Medication Delivery Device
US20120172812A1 (en) * 2009-06-01 2012-07-05 Sanofi-Aventis Deutschland Gmbh Dose setting mechanism for priming a drug delivery device

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3302462A (en) * 1964-05-25 1967-02-07 Dow Chemical Co Pipetting device with stop mechanism
DE4112259A1 (en) * 1991-04-15 1992-10-22 Medico Dev Investment Co INJECTION DEVICE
WO1992018180A1 (en) 1991-04-22 1992-10-29 Helldin Nils Goeran A syringe, including a rod and a piston
US5423752A (en) * 1992-07-31 1995-06-13 Habley Medical Technology Corporation Variable proportion dispenser with cartridge replacement assembly
DE9301334U1 (en) 1993-02-01 1993-04-01 Ing. Lang & Menke Gmbh, 5870 Hemer, De
US5411377A (en) 1993-03-17 1995-05-02 Houser; Michael P. Mass displacement wave energy conversion system
US5584815A (en) * 1993-04-02 1996-12-17 Eli Lilly And Company Multi-cartridge medication injection device
DK170604B1 (en) 1993-12-07 1995-11-13 Niels Erik Holm Aps Metering unit for metering measured-off quantities of a liquid
US5514097A (en) * 1994-02-14 1996-05-07 Genentech, Inc. Self administered injection pen apparatus and method
US5792117A (en) * 1994-07-22 1998-08-11 Raya Systems, Inc. Apparatus for optically determining and electronically recording injection doses in syringes
AU1860697A (en) * 1995-09-08 1997-07-28 Visionary Medical Products Corporation Pen-type injector drive mechanism
EP0848624B1 (en) * 1996-07-05 2005-10-26 Tecpharma Licensing AG Injection device for injection of liquid
ATE240755T1 (en) 1997-07-14 2003-06-15 Novo Nordisk As CYLINDRICAL AMPOULE
DE29818721U1 (en) 1998-10-21 2000-03-02 Medico Dev Investment Co Injection device
TW453884B (en) 1999-09-16 2001-09-11 Novo Nordisk As Dose setting limiter
CA2448726C (en) * 2001-07-16 2012-01-31 Eli Lilly And Company Medication dispensing apparatus configured for rotate to prime and pull/push to inject functionality
AU2003216521A1 (en) 2002-03-18 2003-10-08 Eli Lilly And Company Medication dispensing apparatus with gear set for mechanical advantage
US20040225258A1 (en) 2002-03-30 2004-11-11 Ernest Balestracci Tamper evident overcap for a container
DE10229138B4 (en) * 2002-06-28 2008-01-31 Tecpharma Licensing Ag Product diverter with piston rod emergency reset
DE10239784B4 (en) 2002-08-29 2004-12-30 Tecpharma Licensing Ag Injection, infusion or inhalation device with dose display device
EP1545663B1 (en) * 2002-10-01 2006-08-30 Becton Dickinson and Company Medication delivery pen
DE10302163A1 (en) 2003-01-21 2004-07-29 Tecpharma Licensing Ag Unit administering medicament, includes inspection window showing section of scale against which internal mark shows dose set
US7329241B2 (en) * 2003-02-14 2008-02-12 Valeant Pharmaceuticals North America Drug delivery system for administering an adjustable preset dose
GB0304822D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
WO2004078293A1 (en) 2003-03-05 2004-09-16 3Ip Co., Ltd. Electronic dart game set and metod of assembling the same
US20040186437A1 (en) * 2003-03-20 2004-09-23 Frenette Claude E. Content-coded medical syringe, syringe set and syringe content identification method
WO2005021072A1 (en) 2003-09-03 2005-03-10 Novo Nordisk A/S Threaded rod and nut assembly
DE20317377U1 (en) * 2003-11-03 2005-03-17 B D Medico S A R L injection device
DE10351597A1 (en) 2003-11-05 2005-06-16 Tecpharma Licensing Ag Device and autoinjector for administration of an injectable product, useful in drug administration, e.g. for intravenous injection, comprises a housing, a product reservoir, piston, priming mechanism and metering element
CN101022843B (en) 2004-09-02 2010-12-29 塞诺菲-安万特德国有限公司 Method of assembly of drug delivery devices
EP2047878B1 (en) 2004-12-01 2011-02-23 Novo Nordisk A/S Injection Device
US9457154B2 (en) 2005-01-25 2016-10-04 Novo Nordisk A/S Injection device with an end of dose feedback mechanism
DE102005063311A1 (en) 2005-02-23 2006-08-24 Tecpharma Licensing Ag Dispensing device for medical, diagnosic/cosmetic product, comprises indicator cylinder, housing, promoters for promoting the product relative to the housing, dosing equipment for adjusting product dose, and coupling elements
WO2006089767A1 (en) 2005-02-28 2006-08-31 Novo Nordisk A/S Dose setting mechanism for an injection device capable of presetting a maximum dose
US20080221530A1 (en) 2005-04-24 2008-09-11 Novo Nordisk A/S Injection Device With A GearBox
DE102005022532A1 (en) * 2005-05-17 2006-11-23 Tecpharma Licensing Ag Delivery device with forced priming
DE102005032705B4 (en) * 2005-05-24 2009-01-08 Tecpharma Licensing Ag Plastic spring
JP4827922B2 (en) 2005-07-27 2011-11-30 ノボ・ノルデイスク・エー/エス Dosing mechanism of an injection device that limits the setting of the dose corresponding to the remaining amount of the drug
EP1965846A1 (en) 2005-12-08 2008-09-10 Eli Lilly And Company Dose indicating assembly of a pharmaceutical injection device
DE102005060928A1 (en) 2005-12-20 2007-06-28 Tecpharma Licensing Ag Injection device with axially overlapping metering or display element
CN101400394B (en) * 2006-03-10 2012-07-04 诺沃-诺迪斯克有限公司 An injection device having a gearing arrangement
DE102006038123C5 (en) 2006-08-14 2012-05-03 Tecpharma Licensing Ag Injection device with mechanical lock
DE102007001432A1 (en) * 2006-08-14 2008-02-21 Tecpharma Licensing Ag Blocking unit for dosing mechanism of injection device, has retaining unit acting together with dosing mechanism or dosing unit such that adjusting movement of mechanism or dosing unit in starting position of blocking unit is prevented
PL3626289T3 (en) 2006-09-15 2021-06-14 Ypsomed Ag Injection device comprising an improved delivery element
GB2443390A (en) 2006-11-03 2008-05-07 Owen Mumford Ltd Medicine delivery apparatus
EP1923084A1 (en) 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
CA2681023C (en) 2007-03-23 2015-11-03 Novo Nordisk A/S An injection device comprising a locking nut
DE102007019124A1 (en) 2007-04-23 2008-11-06 Tecpharma Licensing Ag Reversible metering device for an injection device
DE102007026083A1 (en) 2007-05-25 2008-11-27 Haselmeier S.A.R.L. injection device

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US533575A (en) 1895-02-05 wilkens
US5092842A (en) * 1987-05-08 1992-03-03 Wilhelm Haselmeier Gmbh & Co. Injection device with a cocking element and a second setting element
US5226895A (en) * 1989-06-05 1993-07-13 Eli Lilly And Company Multiple dose injection pen
US5304152A (en) 1990-03-29 1994-04-19 Bernard Sams Dispensing device
US5480387A (en) 1991-07-24 1996-01-02 Medico Development Investment Company Injection device
US5626566A (en) 1991-10-18 1997-05-06 Novo Nordisk A/S Large dose pen
US5279586A (en) 1992-02-04 1994-01-18 Becton, Dickinson And Company Reusable medication delivery pen
US5320609A (en) 1992-12-07 1994-06-14 Habley Medical Technology Corporation Automatic pharmaceutical dispensing syringe
US5383865A (en) 1993-03-15 1995-01-24 Eli Lilly And Company Medication dispensing device
US5505704A (en) 1993-04-02 1996-04-09 Eli Lilly And Company Manifold medication injection apparatus and method
US5582598A (en) 1994-09-19 1996-12-10 Becton Dickinson And Company Medication delivery pen with variable increment dose scale
US6221046B1 (en) 1995-03-07 2001-04-24 Eli Lilly And Company Recyclable medication dispensing device
US5674204A (en) 1995-09-19 1997-10-07 Becton Dickinson And Company Medication delivery pen cap actuated dose delivery clutch
WO1997010864A1 (en) 1995-09-19 1997-03-27 Becton Dickinson And Company Pen injector with cartridge loading mechanism
US5688251A (en) * 1995-09-19 1997-11-18 Becton Dickinson And Company Cartridge loading and priming mechanism for a pen injector
JPH11511364A (en) 1995-09-19 1999-10-05 ベクトン・ディキンソン・アンド・カンパニー Pen syringe with cartridge loading mechanism
US6193698B1 (en) 1997-07-18 2001-02-27 Disetronic Licensing Ag System for locking a dosing button in a device for the adminstration of a product to be injected
US5921966A (en) 1997-08-11 1999-07-13 Becton Dickinson And Company Medication delivery pen having an improved clutch assembly
WO1999038554A1 (en) 1998-01-30 1999-08-05 Novo Nordisk A/S An injection syringe
US6004297A (en) 1998-01-30 1999-12-21 Novo Nordisk A/S Injection syringe
US6235004B1 (en) 1998-01-30 2001-05-22 Novo Nordisk A/S Injection syringe
EP0937472A2 (en) 1998-02-20 1999-08-25 Becton Dickinson and Company Repeat-dose medication delivery pen
EP0937471A2 (en) 1998-02-20 1999-08-25 Becton Dickinson and Company Medication delivery pen
US5961495A (en) 1998-02-20 1999-10-05 Becton, Dickinson And Company Medication delivery pen having a priming mechanism
EP0937476A2 (en) 1998-02-23 1999-08-25 Becton, Dickinson and Company Low-cost medication delivery pen
US6248095B1 (en) 1998-02-23 2001-06-19 Becton, Dickinson And Company Low-cost medication delivery pen
WO2001010484A1 (en) 1999-08-05 2001-02-15 Becton, Dickinson And Company Medication delivery pen
US6936032B1 (en) * 1999-08-05 2005-08-30 Becton, Dickinson And Company Medication delivery pen
US20030050609A1 (en) 2000-03-24 2003-03-13 Bernard Sams One-way clutch mechanisms and injector devices
US6899698B2 (en) 2000-03-24 2005-05-31 Bernard Sams One-way clutch mechanisms and injector devices
US20020052578A1 (en) 2000-06-16 2002-05-02 Moller Claus Schmidt Injection device
US20040059299A1 (en) 2000-06-16 2004-03-25 Moller Claus Schmidt Injection device
US7241278B2 (en) 2000-06-16 2007-07-10 Novo Nordisk A/S Injection device
US20020120235A1 (en) 2001-01-05 2002-08-29 Christian Enggaard Automatic injection device with reset feature
US20040210199A1 (en) 2001-05-16 2004-10-21 Atterbury William Goodwin Medication injector apparatus with drive assembly that facilitates reset
US7195616B2 (en) * 2001-05-16 2007-03-27 Eli Lilly And Company Medication injector apparatus with drive assembly that facilitates reset
US20040267207A1 (en) 2003-03-03 2004-12-30 Veasey Robert Frederick Drive mechanisms suitable for use in drug delivery devices
US20050113765A1 (en) 2003-03-03 2005-05-26 Veasey Robert F. Pen-type injector
US20080027397A1 (en) * 2003-08-12 2008-01-31 Deruntz Otto D Medication dispensing apparatus with triple screw threads for mechanical advantage
US20070016143A1 (en) * 2003-12-08 2007-01-18 Novo Nordisk A/S Medical delivery device having air shot means
JP2007512932A (en) 2003-12-08 2007-05-24 ノボ・ノルデイスク・エー/エス Pharmaceutical supply device having air shot means
WO2005053778A1 (en) 2003-12-08 2005-06-16 Novo Nordisk A/S A medical delivery device having air shot means
EP1541185A1 (en) 2003-12-08 2005-06-15 Novo Nordisk A/S Automatic syringe with priming mechanism
US20060153693A1 (en) 2004-12-31 2006-07-13 Patrick Fiechter Administering apparatus comprising a service life timer
US20070016142A1 (en) * 2005-05-24 2007-01-18 Stefan Burren Dose metering mechanism for an injection device
US20080183139A1 (en) * 2005-05-24 2008-07-31 Stefan Burren Dose setting mechanism for an injection device
WO2008074897A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S A syringe device
US20090275916A1 (en) 2008-05-02 2009-11-05 Sanofi-Aventis Deutschland Gmbh Medication Delivery Device
US20120172812A1 (en) * 2009-06-01 2012-07-05 Sanofi-Aventis Deutschland Gmbh Dose setting mechanism for priming a drug delivery device

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
European Search Report for European Patent App. No. 09009052, dated Jul. 6, 2010.
International Preliminary Report on Patentability for International App. No. PCT/EP2010/057473, dated Dec. 6, 2011.
International Search Report and Written Opinion for International App. No. PCT/EP2010/057473, completed Sep. 7, 2010.
Office Action for Japanese Patent App. No. 2012-513563, dated Mar. 4, 2014.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433186B2 (en) 2017-12-13 2022-09-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
US11439758B2 (en) 2019-06-05 2022-09-13 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery

Also Published As

Publication number Publication date
JP5690335B2 (en) 2015-03-25
AU2010255809B2 (en) 2014-11-13
US9950116B2 (en) 2018-04-24
IL216481A (en) 2015-06-30
IL216481A0 (en) 2012-01-31
AU2010255809A1 (en) 2011-12-22
EP2437812B1 (en) 2018-01-10
US20120172812A1 (en) 2012-07-05
WO2010139634A1 (en) 2010-12-09
CN102448518A (en) 2012-05-09
CN102448518B (en) 2014-09-17
US20100324496A1 (en) 2010-12-23
EP2437812A1 (en) 2012-04-11
DK2437812T3 (en) 2018-04-23
US11471602B2 (en) 2022-10-18
BRPI1014730A2 (en) 2016-04-12
US20180207364A1 (en) 2018-07-26
CA2762425A1 (en) 2010-12-09
JP2012528622A (en) 2012-11-15

Similar Documents

Publication Publication Date Title
US9849244B2 (en) Dose setting mechanism for priming a drug delivery device
US9408978B2 (en) Dose setting mechanism for priming a drug delivery device
US9399099B2 (en) Dose setting mechanism for a drug delivery device
US8790315B2 (en) Dose setting mechanism for a drug delivery device
US9533100B2 (en) Dose setting mechanism for priming a drug delivery device
US8795239B2 (en) Biasing mechanism for a drug delivery device
US9138541B2 (en) Drive mechanism for a drug delivery device

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLUMPTRE, DAVID;DAVIES, JAMES;JONES, CHRISTOPHER;AND OTHERS;SIGNING DATES FROM 20120229 TO 20120302;REEL/FRAME:027851/0303

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4